PURPOSE OF REVIEW: This review will discuss the role of antiretroviral therapy to treat primary HIV infection (PHI) as a strategy to prevent onward viral transmission. RECENT FINDINGS: Novel technology has greatly enhanced the appreciation of the characteristics of recently transmitted HIV-1 variants. Recent primate data demonstrate marked enhanced infectiousness of viral variants isolated from acutely infected macaques compared with viruses isolated from animals in the chronic phase of disease. These data are supported by phylogenetic analyses of recently transmitted cases in humans, implying that individuals with PHI may contribute disproportionately to onward transmission at a population level. SUMMARY: In the absence of randomized clinical trial data supporting individual benefit of antiretroviral therapy, targeting and treating individuals with PHI as a public health intervention strategy represent a paradigm shift from current treatment strategies based around proven individual benefit alone. However, there is increasing evidence that PHI contributes disproportionately to viral transmission at a population level and failure to incorporate the potential role PHI plays, particularly in focused epidemics, maybe a naïve omission of many of the current mathematical models evaluating the impact of universal test and treat on population-level HIV incidence.
PURPOSE OF REVIEW: This review will discuss the role of antiretroviral therapy to treat primary HIV infection (PHI) as a strategy to prevent onward viral transmission. RECENT FINDINGS: Novel technology has greatly enhanced the appreciation of the characteristics of recently transmitted HIV-1 variants. Recent primate data demonstrate marked enhanced infectiousness of viral variants isolated from acutely infected macaques compared with viruses isolated from animals in the chronic phase of disease. These data are supported by phylogenetic analyses of recently transmitted cases in humans, implying that individuals with PHI may contribute disproportionately to onward transmission at a population level. SUMMARY: In the absence of randomized clinical trial data supporting individual benefit of antiretroviral therapy, targeting and treating individuals with PHI as a public health intervention strategy represent a paradigm shift from current treatment strategies based around proven individual benefit alone. However, there is increasing evidence that PHI contributes disproportionately to viral transmission at a population level and failure to incorporate the potential role PHI plays, particularly in focused epidemics, maybe a naïve omission of many of the current mathematical models evaluating the impact of universal test and treat on population-level HIV incidence.
Authors: Dimitrios Paraskevis; Georgios K Nikolopoulos; Vana Sypsa; Mina Psichogiou; Katerina Pantavou; Evangelia Kostaki; Timokratis Karamitros; Dimitra Paraskeva; John Schneider; Melpomeni Malliori; Samuel R Friedman; Don C Des Jarlais; Georgios L Daikos; Angelos Hatzakis Journal: Infect Genet Evol Date: 2018-04-10 Impact factor: 3.342
Authors: Bluma G Brenner; Michel Roger; David Stephens; Daniela Moisi; Isabelle Hardy; Jonathan Weinberg; Reuven Turgel; Hugues Charest; James Koopman; Mark A Wainberg Journal: J Infect Dis Date: 2011-10-01 Impact factor: 5.226
Authors: Maile Y Karris; Yu-ting Kao; Derek Patel; Matthew Dawson; Steven P Woods; Florin Vaida; Celsa Spina; Douglas Richman; Susan Little; Davey M Smith Journal: AIDS Date: 2014-03-27 Impact factor: 4.177
Authors: Aditya Khanna; Steven M Goodreau; Dan Wohlfeiler; Eric Daar; Susan Little; Pamina M Gorbach Journal: Ann Epidemiol Date: 2014-10-07 Impact factor: 3.797
Authors: Patrick O'Byrne; Jacqueline Willmore; Alyssa Bryan; Dara S Friedman; Andrew Hendriks; Cynthia Horvath; Dominique Massenat; Christiane Bouchard; Robert S Remis; Vera Etches Journal: BMC Public Health Date: 2013-02-01 Impact factor: 3.295
Authors: Elizabeth Hamlyn; Fiona M Ewings; Kholoud Porter; David A Cooper; Giuseppe Tambussi; Mauro Schechter; Court Pedersen; Jason F Okulicz; Myra McClure; Abdel Babiker; Jonathan Weber; Sarah Fidler Journal: PLoS One Date: 2012-08-31 Impact factor: 3.240